NovAccel Raises 1.2 Billion JPY in Post-Seed Round Funding
NQ Score
88/100
N1 Content Completeness
90
AI Summary (NQ-processed)
NovAccel, a developer of small superconducting accelerators for medical radioisotope production, has secured 1.2 billion JPY in a post-seed funding round, bringing its total raised capital to approximately 2.0 billion JPY. The funds will accelerate the establishment of an international radium-226 (Ra-226) procurement system and the completion of its medical radioisotope manufacturing facility by the end of the year, essential for the stable supply of Actinium-225 (Ac-225) for next-generation cancer therapies.
AI Analysis
Frequently Asked Questions
- Q: How much post-seed funding did NovAccel Co., Ltd. raise to accelerate its medical radioisotope production?
- A: NovAccel Co., Ltd. raised 1.2 billion JPY in a post-seed round through third-party allocation of shares.
- Q: Who is the newly appointed external director of NovAccel Co., Ltd. following the latest investment round?
- A: Ms. Hiroko Kimura from Fast Track Initiative No. 4 Investment Limited Partnership has been appointed as the external director.
- Q: Which organization led the Global Radium Initiative that NovAccel Co., Ltd. joined in September 2025?
- A: The International Atomic Energy Agency led the Global Radium Initiative which NovAccel Co., Ltd. joined in September 2025.
- Q: Where is the headquarters of NovAccel Co., Ltd., the developer of the RiSA superconducting accelerator, located?
- A: The headquarters of NovAccel Co., Ltd. is located in Tsuchiura City, Ibaraki Prefecture, Japan.
- Q: What raw material is NovAccel Co., Ltd. procuring to establish a stable global supply of Actinium-225?
- A: NovAccel Co., Ltd. is procuring Radium-226 to establish a global supply of Actinium-225 for Targeted Alpha Therapy.